{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T05:14:01Z","timestamp":1739078041826,"version":"3.37.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T00:00:00Z","timestamp":1236816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1479-5876-7-16","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T19:13:21Z","timestamp":1236885201000},"source":"Crossref","is-referenced-by-count":7,"title":["Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments"],"prefix":"10.1186","volume":"7","author":[{"given":"Dieter","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Christofferson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Stridsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin","family":"Lindhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faranak","family":"Azarbayjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,12]]},"reference":[{"key":"327_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0959-8049(00)00058-7","volume":"36","author":"SJ Cotterill","year":"2000","unstructured":"Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, Imeson J: Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982\u20131992. Eur J Cancer. 2000, 36: 901-908. 10.1016\/S0959-8049(00)00058-7.","journal-title":"Eur J Cancer"},{"key":"327_CR2","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1200\/JCO.2003.05.191","volume":"21","author":"B De Bernardi","year":"2003","unstructured":"De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A: Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol. 2003, 21: 1592-1601. 10.1200\/JCO.2003.05.191.","journal-title":"J Clin Oncol"},{"key":"327_CR3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1996.14.2.405","volume":"14","author":"D Meitar","year":"1996","unstructured":"Meitar D, Crawford SE, Rademaker AW, Cohn SL: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 1996, 14: 405-414.","journal-title":"J Clin Oncol"},{"key":"327_CR4","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-07-0237","volume":"13","author":"R Peddinti","year":"2007","unstructured":"Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, Pawel B, Salwen HR, Maris JM, Cohn SL: Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin Cancer Res. 2007, 13: 3499-3506. 10.1158\/1078-0432.CCR-07-0237.","journal-title":"Clin Cancer Res"},{"key":"327_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1023\/A:1024564817563","volume":"5","author":"U Backman","year":"2002","unstructured":"Backman U, Svensson A, Christofferson R: Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis. 2002, 5: 267-274. 10.1023\/A:1024564817563.","journal-title":"Angiogenesis"},{"key":"327_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1203\/01.pdr.0000242494.94000.52","volume":"60","author":"L Segerstrom","year":"2006","unstructured":"Segerstrom L, Fuchs D, Backman U, Holmquist K, Christofferson R, Azarbayjani F: The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts. Pediatr Res. 2006, 60: 576-581. 10.1203\/01.pdr.0000242494.94000.52.","journal-title":"Pediatr Res"},{"key":"327_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1126\/science.1125950","volume":"312","author":"RS Kerbel","year":"2006","unstructured":"Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science. 2006, 312: 1171-1175. 10.1126\/science.1125950.","journal-title":"Science"},{"key":"327_CR8","first-page":"4342","volume":"63","author":"F Bertolini","year":"2003","unstructured":"Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63: 4342-4346.","journal-title":"Cancer Res"},{"key":"327_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1200\/JCO.2005.07.093","volume":"23","author":"K Pietras","year":"2005","unstructured":"Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose \"chemo-switch\" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005, 23: 939-952. 10.1200\/JCO.2005.07.093.","journal-title":"J Clin Oncol"},{"key":"327_CR10","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000, 105: R15-24. 10.1172\/JCI8829.","journal-title":"J Clin Invest"},{"key":"327_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004, 4: 423-436. 10.1038\/nrc1369.","journal-title":"Nat Rev Cancer"},{"key":"327_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.bbrc.2008.01.019","volume":"367","author":"UH Olesen","year":"2008","unstructured":"Olesen UH, Christensen MK, Bjorkling F, Jaattela M, Jensen PB, Sehested M, Nielsen SJ: Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008, 367: 799-804. 10.1016\/j.bbrc.2008.01.019.","journal-title":"Biochem Biophys Res Commun"},{"key":"327_CR13","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0022-3565(24)29239-9","volume":"299","author":"SB Hassan","year":"2001","unstructured":"Hassan SB, Jonsson E, Larsson R, Karlsson MO: Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. J Pharmacol Exp Ther. 2001, 299: 1140-1147.","journal-title":"J Pharmacol Exp Ther"},{"key":"327_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000091754","volume":"82","author":"V Johanson","year":"2005","unstructured":"Johanson V, Arvidsson Y, Kolby L, Bernhardt P, Sward C, Nilsson O, Ahlman H: Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice. Neuroendocrinology. 2005, 82: 171-176. 10.1159\/000091754.","journal-title":"Neuroendocrinology"},{"key":"327_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00001813-200401000-00010","volume":"15","author":"P Hovstadius","year":"2004","unstructured":"Hovstadius P, Lindhagen E, Hassan S, Nilsson K, Jernberg-Wiklund H, Nygren P, Binderup L, Larsson R: Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. Anticancer Drugs. 2004, 15: 63-70. 10.1097\/00001813-200401000-00010.","journal-title":"Anticancer Drugs"},{"key":"327_CR16","first-page":"5751","volume":"59","author":"PJ Hjarnaa","year":"1999","unstructured":"Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L: CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 1999, 59: 5751-5757.","journal-title":"Cancer Res"},{"key":"327_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1203\/00006450-200205000-00011","volume":"51","author":"A Svensson","year":"2002","unstructured":"Svensson A, Backman U, Jonsson E, Larsson R, Christofferson R: CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr Res. 2002, 51: 607-611.","journal-title":"Pediatr Res"},{"key":"327_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ejca.2004.12.023","volume":"41","author":"A Ravaud","year":"2005","unstructured":"Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, Droz JP, Fumoleau P, Twelves C: Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG\/EORTC study. Eur J Cancer. 2005, 41: 702-707. 10.1016\/j.ejca.2004.12.023.","journal-title":"Eur J Cancer"},{"key":"327_CR19","first-page":"2843","volume":"8","author":"P Hovstadius","year":"2002","unstructured":"Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Karlsson MO, Lonnebo A, Ahlgren J: A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res. 2002, 8: 2843-2850.","journal-title":"Clin Cancer Res"},{"key":"327_CR20","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0022-3468(98)90281-0","volume":"33","author":"Y Zaizen","year":"1998","unstructured":"Zaizen Y, Taniguchi S, Suita S: The role of cellular motility in the invasion of human neuroblastoma cells with or without N-myc amplification and expression. J Pediatr Surg. 1998, 33: 1765-1770. 10.1016\/S0022-3468(98)90281-0.","journal-title":"J Pediatr Surg"},{"key":"327_CR21","first-page":"3751","volume":"38","author":"JL Biedler","year":"1978","unstructured":"Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 1978, 38: 3751-3757.","journal-title":"Cancer Res"},{"key":"327_CR22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1096\/fj.02-0599fje","volume":"17","author":"N Veitonmaki","year":"2003","unstructured":"Veitonmaki N, Fuxe J, Hultdin M, Roos G, Pettersson RF, Cao Y: Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A\/pRb. Faseb J. 2003, 17: 764-766.","journal-title":"Faseb J"},{"key":"327_CR23","first-page":"567","volume":"4","author":"R Larsson","year":"1990","unstructured":"Larsson R, Nygren P, Ekberg M, Slater L: Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia. 1990, 4: 567-571.","journal-title":"Leukemia"},{"key":"327_CR24","first-page":"189","volume":"3","author":"N Welsh","year":"2000","unstructured":"Welsh N: Assessment of apoptosis and necrosis in isolated islets of Langerhans: methological considerations. Curr Top Biochem Res. 2000, 3: 189-200.","journal-title":"Curr Top Biochem Res"},{"key":"327_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1203\/01.PDR.0000156508.68065.AA","volume":"57","author":"U Backman","year":"2005","unstructured":"Backman U, Christofferson R: The selective class III\/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res. 2005, 57: 690-695. 10.1203\/01.PDR.0000156508.68065.AA.","journal-title":"Pediatr Res"},{"key":"327_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0002-9440(10)65286-8","volume":"154","author":"E Wassberg","year":"1999","unstructured":"Wassberg E, Hedborg F, Skoldenberg E, Stridsberg M, Christofferson R: Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am J Pathol. 1999, 154: 395-403.","journal-title":"Am J Pathol"},{"key":"327_CR27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.3-4-253","volume":"3","author":"JK Simpson","year":"1998","unstructured":"Simpson JK, Gaze MN: Current Management of Neuroblastoma. Oncologist. 1998, 3: 253-262.","journal-title":"Oncologist"},{"key":"327_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00043426-199905000-00005","volume":"21","author":"SG DuBois","year":"1999","unstructured":"DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H: Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999, 21: 181-189. 10.1097\/00043426-199905000-00005.","journal-title":"J Pediatr Hematol Oncol"},{"key":"327_CR29","first-page":"47","volume":"18","author":"GN Hendy","year":"1995","unstructured":"Hendy GN, Bevan S, Mattei MG, Mouland AJ: Chromogranin A. Clin Invest Med. 1995, 18: 47-65.","journal-title":"Clin Invest Med"},{"key":"327_CR30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1172\/JCI114604","volume":"85","author":"RJ Hsiao","year":"1990","unstructured":"Hsiao RJ, Seeger RC, Yu AL, O'Connor DT: Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest. 1990, 85: 1555-1559. 10.1172\/JCI114604.","journal-title":"J Clin Invest"},{"key":"327_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1677\/joe.0.1510225","volume":"151","author":"E Wassberg","year":"1996","unstructured":"Wassberg E, Stridsberg M, Christofferson R: Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. J Endocrinol. 1996, 151: 225-230. 10.1677\/joe.0.1510225.","journal-title":"J Endocrinol"},{"issue":"Suppl 2","key":"327_CR32","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1093\/annonc\/12.suppl_2.S69","volume":"12","author":"E Seregni","year":"2001","unstructured":"Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol. 2001, 12 (Suppl 2): S69-72. 10.1023\/A:1012434005852.","journal-title":"Ann Oncol"},{"key":"327_CR33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/00001813-200208000-00008","volume":"13","author":"BM Frost","year":"2002","unstructured":"Frost BM, Lonnerholm G, Nygren P, Larsson R, Lindhagen E: In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. Anticancer Drugs. 2002, 13: 735-742. 10.1097\/00001813-200208000-00008.","journal-title":"Anticancer Drugs"},{"key":"327_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0959-8049(00)00375-0","volume":"37","author":"P Martinsson","year":"2001","unstructured":"Martinsson P, Liminga G, Dhar S, de la Torre M, Lukinius A, Jonsson E, Bashir Hassan S, Binderup L, Kristensen J, Larsson R: Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells. Eur J Cancer. 2001, 37: 260-267. 10.1016\/S0959-8049(00)00375-0.","journal-title":"Eur J Cancer"},{"key":"327_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/00001813-200111000-00005","volume":"12","author":"A Aleskog","year":"2001","unstructured":"Aleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Hoglund M, Tholander B, Binderup L, Larsson R, Jonsson E: Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs. 2001, 12: 821-827. 10.1097\/00001813-200111000-00005.","journal-title":"Anticancer Drugs"},{"key":"327_CR36","first-page":"4342","volume":"51","author":"PG Montaldo","year":"1991","unstructured":"Montaldo PG, Lanciotti M, Casalaro A, Cornaglia-Ferraris P, Ponzoni M: Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res. 1991, 51: 4342-4346.","journal-title":"Cancer Res"},{"key":"327_CR37","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/sj.gt.3300905","volume":"6","author":"M Boyd","year":"1999","unstructured":"Boyd M, Cunningham SH, Brown MM, Mairs RJ, Wheldon TE: Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine. Gene Ther. 1999, 6: 1147-1152. 10.1038\/sj.gt.3300905.","journal-title":"Gene Ther"},{"key":"327_CR38","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/0959-8049(95)00039-L","volume":"31A","author":"HN Lode","year":"1995","unstructured":"Lode HN, Bruchelt G, Seitz G, Gebhardt S, Gekeler V, Niethammer D, Beck J: Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer. 1995, 31A: 586-590. 10.1016\/0959-8049(95)00039-L.","journal-title":"Eur J Cancer"},{"key":"327_CR39","first-page":"1172","volume":"45","author":"BH Kushner","year":"2004","unstructured":"Kushner BH: Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004, 45: 1172-1188.","journal-title":"J Nucl Med"},{"key":"327_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ddr.10353","volume":"61","author":"E Lindhagen","year":"2004","unstructured":"Lindhagen E, Hjarnaa PJ, Friberg LE, Latini S, Larsson R: Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828. Drug Dev Res. 2004, 61: 218-226. 10.1002\/ddr.10353.","journal-title":"Drug Dev Res"},{"key":"327_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejps.2005.02.006","volume":"25","author":"LE Friberg","year":"2005","unstructured":"Friberg LE, Hassan SB, Lindhagen E, Larsson R, Karlsson MO: Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. Eur J Pharm Sci. 2005, 25: 163-173. 10.1016\/j.ejps.2005.02.006.","journal-title":"Eur J Pharm Sci"},{"key":"327_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307: 58-62. 10.1126\/science.1104819.","journal-title":"Science"},{"key":"327_CR43","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0090-9556(25)08440-5","volume":"22","author":"KS Lown","year":"1994","unstructured":"Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994, 22: 947-955.","journal-title":"Drug Metab Dispos"},{"key":"327_CR44","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1016\/j.bmcl.2005.03.064","volume":"15","author":"E Binderup","year":"2005","unstructured":"Binderup E, Bjorkling F, Hjarnaa PV, Latini S, Baltzer B, Carlsen M, Binderup L: EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorg Med Chem Lett. 2005, 15: 2491-2494. 10.1016\/j.bmcl.2005.03.064.","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-7-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1479-5876-7-16\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-7-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T10:26:29Z","timestamp":1739010389000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-7-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-7-16","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2009,3,12]]},"article-number":"16"}}